Latest News

(UroToday.com) As part of the game-changing session at the European Association of Urology 2021 Annual Meeting, Silke Gillessen discussed the recently published TheraP1 and VISION2 trials. Dr. Gillessen notes that in the metastatic castration-resistant prostate cancer (mCRPC) setting, we now have several treatment options that offer a survival benefit, including abiraterone, cabazitaxel, docetaxel, enzalutamide, radium-223, sipuleucel-T, […]

(UroToday.com)  The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Virtual Meeting included a presentation by Dr. Pierre Blanchard discussing the role of imaging-guided treatment for recurrent metastatic hormone-sensitive prostate cancer (mHSPC).   

(UroToday.com) At the European Association of Urology (EAU) 2021 Annual Meeting’s plenary session on the treatment for metastatic hormone-sensitive prostate cancer, Dr. Declan Murphy presented a state of the art lecture on the role of modern imaging for de novo versus recurrent metastatic hormone-sensitive prostate cancer (mHSPC). 

(UroToday.com) The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Meeting included a presentation by Dr. Tobias Maurer discussing the role of imaging-guided surgical treatment for recurrent metastatic hormone sensitive prostate cancer (mHSPC). Dr. Maurer started his presentation by emphasizing that the most recent EAU guidelines do not favor salvage […]

(UroToday.com) Dr. Piet Ost discussed results of a pooled analysis of prospective trials assessing metastasis-directed therapy for oligorecurrent prostate cancer at the 2021 EAU’s annual meeting metastatic prostate cancer session. To date, prospective data for metastasis-directed therapy for oligorecurrent prostate cancer have been limited to single arm or small phase 2 randomized studies. The objective of […]

(UroToday.com) At the 2021 EAU annual meeting, Dr. Klara Kvorning Ternov presented data from the HEAT randomized trial assessing fatigue, quality-of-life and metabolic changes in men treated with enzalutamide versus abiraterone + prednisone. Men with metastatic castration-resistant prostate cancer (mCRPC) often experience fatigue, impaired quality of life and have an increased risk of cardiovascular disease and type […]

San Francisco, CA (UroToday.com) — Men over 60 with low-risk prostate cancer could spend ten years with no active treatment, have a better sex life as a result, yet still be very unlikely to die from the disease, new research has found.

(UroToday.com)  In the Guideline Session II: Prostate Cancer: cN+ in newly diagnosed patients during the 2021 European Association of Urology meeting, Dr. Guillaume Ploussard, armed with more data, argues against the need for more than ADT as systemic therapy for cN+ prostate cancer. He also provides the guideline point of view on this topic. 

(UroToday.com) Dr. Thomas Wiegel reviews the guideline points of view for local treatment in the setting of clinically node positive prostate cancer. He reviews the role of local control, the options of local therapy (RP or EBRT +/- ADT), further potential improvements and the current EAU 2021 guideline position.

Despite high level evidence supporting the use of pharmacotherapy therapy for the prevention of kidney stones, adherence to medications is often poor because of side effects, inconvenience and cost.